Mar 05, 2024 / 02:10PM GMT
Yaron Benjamin Werber - TD Cowen, Research Division - MD & Senior Biotechnology Analyst
All right. Well, welcome once again to the 44th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the Biotech team, and it's a great pleasure to moderate the fireside chat next with Amgen, first fireside chat for the day, so have very high expectations. With us today is Peter Griffith, the[LM1]Chief Financial Officer; Paul Burton, Chief Medical Officer; Justin Claeys, VP of IR; Casey in the audience as well. So gentlemen, thanks for joining us. We appreciate it. Peter, let me turn it over to you opening remarks, and then we'll dive into Q&A.
Peter H. Griffith - Amgen Inc. - Executive VP & CFO
Thank you, Yaron. Thank you, TD Cowen. It's great to be here at the 44th conference. Listen, we're here today on behalf of 27,000 plus colleagues at Amgen. Our mission is to serve patients. And this is an exciting time for Amgen. We see significant long-term growth opportunities across all 4 of our therapeutic pillars.
Numerous catalysts this year,
Amgen Inc at TD Cowen Health Care Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot